Regorafenib [BAY 73-4506]
| Code | Size | Price |
|---|
| AG-CR1-3623-M005 | 5 mg | £40.00 |
Quantity:
| AG-CR1-3623-M025 | 25 mg | £90.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: n/a
Antibody Clone: n/a
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
BAY 73-4506; Fluoro-Sorafenib
Appearance:
Light pink to white solid.
CAS:
755037-03-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light.
Hazards:
H302, H315, H319, H335
InChi:
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
InChiKey:
FNHKPVJBJVTLMP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 755037-03-7. Formula: C21H15ClF4N4O3. MW: 482.8. Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent. Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively.
MDL:
MFCD16038047
Molecular Formula:
C21H15ClF4N4O3
Molecular Weight:
482.8
Package Type:
Vial
Precautions:
P261, P280, P301, P312, P302, P352, P304, P340, P305, P351, P338
Product Description:
Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent. Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Solubility Chemicals:
Soluble in DMSO (>50mg/ml). Slightly soluble in ethanol (1mg/ml). Insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity: S.M. Wilhelm, et al.; Int. J. Cancer 129, 245 (2011) | Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors: G.D. Demetri; Semin. Oncol. 38, S10 (2011) | Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib: K.A. Lyseng-Williamson, et al.; BioDrugs 27, 525 (2013) (Review) | Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors: D.J. Crona, et al.; Ann. Pharmacother. 47, 1685 (2013) (Review) | Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer: R. Schmieder, et al.; Int. J. Cancer 135, 1487 (2014) | Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis: Z. Weng, et al.; Toxicology 327, 10 (2015) | Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling: T. Goncharov, et al.; Mol. Cell. 69, 551 (2018)
Related Products
| Product Name | Product Code | Supplier | Ruxolitinib | AG-CR1-3624 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|